U.S. Markets close in 3 hrs 49 mins

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.20+0.22 (+4.42%)
As of 12:10PM EDT. Market open.
People also watch
  • Need to be acquired by $GILD. The resources of Gilead and the immune therapy of IMGN would be huge.
  • Sweet
    Go baby go, $6 coming
  • Could be good if they have unloaded the $50million worth of new shares through Cowen and Co. at this price. Will be less than 10 million shares of dilution :-)
  • HUGE blocks all day!!!
  • (AXSM) Market Cap $92 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $92 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $92 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23.5 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation May

    HUGE Pipeline targeting Billion Dollar Markets:

    AXS-05 Treatment Resistant Depression in Phase 3......Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3.......No approved medication = unmet medical need. 2M patients in the U.S.

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status).......No approved drug = high unmet need. 80,000 new cases per year in the U.S.

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track).........7M patients in the U.S.

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 ......1.6M patients in the U.S.

  • Rising with good volume. On watch for clear above 4.99. Technical strong buy at stoxline.
  • Time to hit 5😎
  • Question: Is this the normal pre ASCO run-up followed by a selloff, or is it different this time for IMGN? In my gut it feels different. We shall see.
  • Obviously, somebody likes what they see. Question is, what comes first, secondary or partnership... I'm letting it ride and going with partnership.
  • Does anyone know why it is spiking today?
  • Harry Boxer has posted his Charts of the Day video on IMGN at TheTechTrader site noting: ImmunoGen, Inc. (IMGN) acted well on Thursday, popping 67 cents, or 14%, to 5.40, on nearly 9 million shares traded. That’s the biggest volume since December 30 when it broke out. So, this is significant because it’s at the top of the channel. If it blows through here, I could see it run to the 6 1/2-7 zone, which I would put out a swing on it. It has 5.9 days to cover.
  • congrats, a first ever successful company-run phase II trial in over 25 years. If history is any guide, they will now sell their insider shares and then do a large secondary. Maybe new management is different, but this is what IMGN management has done in the past.
  • Short busting rally on deck $IMGN LONGS hang on for the ride-- Bottom is in
    Double digits could occur anytime
    Big boys are loading there books now
  • Filed a $50,000,000 secondary offering through Cowen and Co.
  • does anyone have any recommendations on how to reconcile the fact that yahoo shows 90% institutional ownership and Ameritrade shows 70%.
  • Everyone who thinks this is a fun little bio raise your hand. It will out shine IMMU in the long run since they have so many partners and shots on the rim. Call me a pumper - I say realist. I have a core and trade the waves quite successfully and have done so for years. GLTL's
  • Anyone know why it's falling $.31 in the after hours?
  • Let's go! 5 bucks next week for sure!
  • what the heck is happening with this? good quarter report and it totally tanks, I thought it would finally go over $5!!!!!!!!!!!
  • Nice upsurge on previously published data - All these little PR's coming out so regularly makes me think a raise is coming - I am out at 4.45 as reckon this is as high as it goes will look to buy back in in the low $3 range - Of course I could be wrong but for me time to bank a decent profit :-)